Journal of clinical virology plus最新文献

{"title":"Assessing the effect of remdesivir alone and in combination with corticosteroids on time to death in COVID-19: A propensity score-matched analysis","authors":"Mohamad Amin Pourhoseingholi ,&nbsp;Mehdi Azizmohammad Looha ,&nbsp;Saba Ilkhani ,&nbsp;Hamidreza Hatamabadi ,&nbsp;Amir Sadeghi ,&nbsp;Seyed Amir Ahmad Safavi-Naini ,&nbsp;Kamran Heidari ,&nbsp;Nazanin Taraghikhah ,&nbsp;Mohammad Mahdi Fallah ,&nbsp;Reyhaneh Kalantar ,&nbsp;Nariman Naderi ,&nbsp;Romina Esbati ,&nbsp;Nastaran Ebrahimi ,&nbsp;Ali Solhpour ,&nbsp;Tannaz Jamialahmadi ,&nbsp;Amirhossein Sahebkar","doi":"10.1016/j.jcvp.2024.100180","DOIUrl":"10.1016/j.jcvp.2024.100180","url":null,"abstract":"<div><h3>Background</h3><p>This study aimed to evaluate the impact of remdesivir, alone or in combination with corticosteroids, on the time to death in COVID-19 patients.</p></div><div><h3>Methods</h3><p>This retrospective cohort study was conducted between March 20, 2020, and March 18, 2021, on 5318 patients with confirmed COVID-19 at three tertiary educational hospitals in Tehran, Iran. The treated group consisted of COVID-19 patients who received remdesivir, either alone or in combination with corticosteroids, while the untreated group included infected patients who did not receive these treatments. The two groups were matched by propensity score matching method, which adjusted for 92 confounding factors such as demographic, sign and symptom, clinical, and treatment-related factors, to provide balanced covariates between the treated and untreated groups.</p></div><div><h3>Results</h3><p>Of the 4,322 patients, 791 received remdesivir alone and 694 received remdesivir combined with corticosteroids. Among the patients who received remdesivir, 456 were male, and the mean (±standard deviation) age was 59.52±16.49 with a median hospitalization stay of 8 (interquartile range: 5–13) days. After applying the nearest neighbor propensity score matching method, there were no significant differences found in the hazard of death between patients who received remdesivir alone and those who did not receive treatment (hazard ratio: 0.94; 95 % confidence interval: 0.76, 1.16). In addition, the combination of remdesivir and corticosteroids was not associated with a reduced hazard of death (hazard ratio: 1.00; 95 % confidence interval: 0.80, 1.26). The median hospitalization stay was significantly longer in the group treated with remdesivir (alone/combined with corticosteroids) compared to the untreated group, both before and after matching.</p></div><div><h3>Conclusion</h3><p>No association was observed between remdesivir treatment (alone/combined with corticosteroids) and a reduced hazard of death among COVID-19 patients. However, longer hospitalization stays were observed in patients receiving remdesivir, either alone or in combination with corticosteroids, compared to the untreated group.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100180"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266703802400005X/pdfft?md5=cc0ab6353901d2e6d1acdc7dc519bd30&pid=1-s2.0-S266703802400005X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140765061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HPV prevalence and genotype distribution among Vietnamese cervical cancer patients in the northern region of Vietnam, from 2018 – 2020","authors":"Le Van Nam ,&nbsp;Hoang Xuan Son ,&nbsp;Le Van Nguyen Bang ,&nbsp;Le Van Duyet","doi":"10.1016/j.jcvp.2024.100182","DOIUrl":"https://doi.org/10.1016/j.jcvp.2024.100182","url":null,"abstract":"<div><h3>Background/purpose</h3><p>HPV infection is the primary cause of cervical cancer, and genotype distribution varies according to geographical location and carcinogenicity. Therefore, identifying HPV genotype and its association with cervical cancer features is critical for screening, diagnosis, and therapy.</p></div><div><h3>Methods</h3><p>Data from Vietnamese women with HPV-positive cervical cancer were collected from the northern region. The HPV genotype was identified using the Cobas^®®4800 HPV system, whereas the nucleotide sequences of the E6, E7, and L1 genes were used to identify lineages and sublineages using DNASTAR, Bioedit, ATGC 7.2, and MEGA 11.0.10 softwares.</p></div><div><h3>Results</h3><p>Of the 180 patients infected with HPV, 82.8 % revealed single infections, and 17.2 % showed multiple infections. HPV16 (64.4 %), HPV18 (28.9 %), and other HPVs (6.7 %) were the most prevalent HPV genotypes. HPV16 lineages included European (sublineage A1 (11.2 %), A2 (1.72 %), and A3 (25.86 %); Asian (sublineage A4 (53.85 %); African-American (sublineage D1 (5.17 %); and Asian-American (sublineage D3 (2.59 %). The HPV18 lineage includes Asian-Ameridian (sublineages A1 (100 %)). HPV18 revealed a higher rate of cervical cancer, cervicitis, warts, and ulcers than HPV16 and other high-risk genotypes in the 35–54–year–old group, but did not show a difference in cancer stages.</p></div><div><h3>Conclusions</h3><p>HPV16 and HPV18 genotypes are common in cervical cancer in northern Vietnam, with European, Asian, and Asian–Amerindian lineages predominating. HPV18 causes cervical cancer at a higher rate than other genotypes in the 35–54–year–old age group; thus, early identification of the genotype is critical for more successful therapy.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100182"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000073/pdfft?md5=1018b5cd7ed013d02bb7bc73e5df9546&pid=1-s2.0-S2667038024000073-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140906183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of intravenous peramivir versus oral oseltamivir in the treatment of influenza in children: A meta-analysis","authors":"Jie Yuan ,&nbsp;Shuhua An ,&nbsp;Zhongfu Zhang","doi":"10.1016/j.jcvp.2024.100179","DOIUrl":"10.1016/j.jcvp.2024.100179","url":null,"abstract":"<div><h3>Objective</h3><p>To investigate the efficacy and safety of intravenous peramivir compared to oral oseltamivir for pediatric influenza by a method of meta-analysis.</p></div><div><h3>Methods</h3><p>Clinical trials involving intravenous peramivir versus oral oseltamivir therapy in children with influenza were searched from six databases until July 2023. Data were processed using Stata 15.0 software.</p></div><div><h3>Results</h3><p>Seven published articles were identified in this review. The combined results exhibited that the clinical effective rate in the peramivir group (76.09 %) was higher than that in the oseltamivir group (58.85 %) (RR= 1.12, 95 %CI: 1.01∼1.24, <em>P</em> = 0.038). The incidence of adverse reactions in the peramivir group (13.31 %) was lower than that in the oseltamivir group (17.34 %) (RR= 0.77, 95 %CI: 0.61–0.96, <em>P</em> = 0.023). Compared with the oseltamivir group, the peramivir group had lower recovery time of body temperature (WMD= -19.81, 95 %CI: -27.58∼-12.04, <em>P</em> &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>Compared with oral oseltamivir, intravenous peramivir has better efficacy and higher safety for pediatric influenza.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100179"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000048/pdfft?md5=3e38732d6d7310f107900a33973c9f81&pid=1-s2.0-S2667038024000048-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140775921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rotavirus strains in children less than 5 years of age: A case control study","authors":"Jasmin Shrestha ,&nbsp;Sanjaya K Shrestha ,&nbsp;Carl Mason ,&nbsp;Siriporn Sornsakrin ,&nbsp;Sasikorn Silapong ,&nbsp;Jwoti Dhakwa ,&nbsp;Shanti Regmi ,&nbsp;Tor A. Strand ,&nbsp;Ashild K. Andreassen ,&nbsp;Susanne Dudman ,&nbsp;Ladaporn Bodhidatta","doi":"10.1016/j.jcvp.2024.100183","DOIUrl":"10.1016/j.jcvp.2024.100183","url":null,"abstract":"<div><h3>Background</h3><p>Globally, rotavirus A (RV) is a leading cause of acute gastroenteritis (AGE) in young children under 5 years. The main aim of this study was to describe the prevalence of RV in children with and without diarrhea whose age ranged from 3 months to 5 years from two different hospitals of Nepal. We also described the diversity of rotavirus circulating during the pre-vaccination period in Nepal between 2006–2009.</p></div><div><h3>Materials and methods</h3><p>A total of 2400 stool samples collected from children's years with diarrhea (cases, <em>N</em> = 1200) and without diarrhea (controls, <em>N</em> = 1200) were tested for the presence of RV by both enzyme-linked immunosorbent assay and real-time reverse transcription polymerase chain reaction (RT-PCR). All samples positive for RT PCR and/or ELISA were further characterized for G and P genotypes by conventional RT-PCR.</p></div><div><h3>Results</h3><p>In total, 500 of the 2398 (20.8 %) samples (424 cases and 76 controls), were positive for RV. The most frequently detected G-types were G12, G1, and G9 and P-types were P[8] and P[6]. The predominant genotypes G12P[6], G12P[8], G1P[8] and G9P[8] were identified in 27.8 %, 24.2 %, 11.8 % and 10.8 % of the samples, respectively.</p></div><div><h3>Conclusion</h3><p>This study observed high prevalence of G12P[6] rotavirus circulating in Nepal before vaccine introduction and they may pose an emerging challenge to current and future vaccine. Therefore, continuous molecular surveillance of circulating genotypes and emerging rotavirus strain should be carried out to better understand the effectiveness of vaccination program.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100183"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000085/pdfft?md5=5c8f236d1aeab98908db98d8dfa55b1f&pid=1-s2.0-S2667038024000085-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141031857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic characterization of influenza A(H1N1)pdm09 virus in 2023 in Huzhou, China","authors":"Deshun Xu ,&nbsp;Liping Chen ,&nbsp;Lei Ji,&nbsp;Wei Yan","doi":"10.1016/j.jcvp.2024.100178","DOIUrl":"https://doi.org/10.1016/j.jcvp.2024.100178","url":null,"abstract":"<div><h3>Introduction</h3><p>Since its identification in April 2009, influenza A(H1N1)pdm09 virus has continued to cause significant outbreaks of respiratory tract infections, including pandemics in humans. In the course of its evolution, the virus has acquired many mutations that cause increased disease severity. Regular molecular surveillance of the virus is essential to mark the evolutionary changes that may cause a shift in viral behavior.</p></div><div><h3>Methods</h3><p>Twenty-five (H1N1)pdm09 isolates from Huzhou, China, in 2023 were randomly selected for whole-genome sequencing along with analysis of nucleotide and amino acid sequence identity, average genetic distance, antigen variation sites, receptor binding sites, pathogenicity, potential glycosylation sites, and drug resistance gene sites.</p></div><div><h3>Results</h3><p>The 25 (H1N1)pdm09 strains and representative 2023–2024 northern hemisphere vaccine strain A/Wisconsin/67/2022 showed nucleotide and amino acid similarity of 98.41 %–99.22 % and 98.41 %–99.36 %, respectively. This virus belongs to the 6B1A.5a.2a evolutionary lineage. There were 19 amino acid variations in hemagglutinin (HA) protein. Substitutions S137P and R142K occurred in the epitope Ca2 cluster. A total of 13 amino acids were mutated in neuraminidase (NA) protein, and 9 key protease active sites and amino acid sites related to NA inhibitor (NAI) resistance were not mutated. Five amino acid sites of matrix-2 (M2) protein associated with drug resistance were not replaced, but amino acid 31 of M2 protein was shown to be N in the 2023 pandemic strain (H1N1)pdm09 and vaccine strain A/Wisconsin/67/2022. There were seven and eight potential glycosylation sites for HA protein and NA protein, respectively. Compared with the vaccine strains, there were no new or missing potential glycosylation sites in the 25 (H1N1)pdm09 influenza virus isolates. No multiple continuous alkaline amino acids were found in the HA cleavage site of the 25 isolates.</p></div><div><h3>Conclusions</h3><p>The recommended vaccine strain A/Wisconsin/67/2022 has good prevention potential against the current circulating influenza (H1N1)pdm09. At present, NAIs have good therapeutic and preventive effects against (H1N1)pdm09 circulating in Huzhou, China, but the virus is naturally resistant to amantadines. At present, the (H1N1)pdm09 strain circulating in Huzhou, China, is characterized by low pathogenicity. However, regular molecular surveillance of (H1N1)pdm09 is important to monitor the behavior of the virus in terms of increases in virulence, drug resistance, and emergence of novel strains.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100178"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000036/pdfft?md5=e6b978e33b57522d816f7d28fad49561&pid=1-s2.0-S2667038024000036-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140030703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences regarding symptoms of SARS-CoV-2-Infection in pediatric and adolescent athletes in comparison to adult athletes","authors":"Karsten Keller ,&nbsp;Oliver Friedrich ,&nbsp;Julia Treiber ,&nbsp;Anne Quermann ,&nbsp;Birgit Friedmann-Bette","doi":"10.1016/j.jcvp.2024.100184","DOIUrl":"10.1016/j.jcvp.2024.100184","url":null,"abstract":"<div><h3>Background</h3><p>Most children are afflicted by a mild SARS-CoV-2-infection course in comparison to adults. However, data about differences between the experienced symptoms of pediatric/adolescent in comparison to adult athletes are sparse.</p></div><div><h3>Methods</h3><p>Competitive athletes of any age, who presented for preparticipation screening 04/2020–10/2021 with confirmed SARS-CoV-2-infection were included in this study, stratified for pediatric/adolescent (≤18years) or adult age (&gt;18years) and both age-groups were compared regarding symptoms.</p></div><div><h3>Results</h3><p>Overall, 157 athletes with former SARS-CoV-2-infection (mean age 22.0 [18.0/27.0] years; 35.0 % females) were included in our study 04/2020 – 10/2021; among them, 40 (25.5 %) were pediatric/adolescent and 117 (74.5 %) adult athletes.</p><p>Pediatric/adolescent athletes had significantly more often an asymptomatic SARS-CoV-2-infection (22.5% vs. 6.0 %, <em>P</em> = 0.003). Symptoms of cold and flu-like symptoms (81.2% vs. 57.5 %, <em>P</em> = 0.003) and neurological symptoms (83.8% vs. 60.0 %, <em>P</em> = 0.002) were more often detected in adult athletes, while respiratory and cardiac symptoms were similar prevalent in both groups.</p><p>Age ≤ 18 years was independently associated with higher prevalence of asymptomatic SARS-CoV-2-infection (OR 5.12 [95 %CI 1.71–15.33], <em>P</em> = 0.004), but reduced occurrence of cold and flu-like symptoms (OR 0.27 [95 %CI 0.12–0.62], <em>P</em> = 0.002) and of neurological symptoms (OR 0.29 [95 %CI 0.13–0.67], <em>P</em> = 0.003). The included athletes were very rarely affected by adverse events. Pneumonia was detected in one adult athlete (0.9% vs. 0 %). None of the included athletes were afflicted by myocarditis or other serious adverse events.</p></div><div><h3>Conclusions</h3><p>Pediatric/adolescent athletes had more often an asymptomatic SARS-CoV-2-infection or were afflicted by only mild symptoms, while adult athletes suffered from larger symptom-burden predominantly driven by neurologic symptoms.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100184"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000097/pdfft?md5=da70512fa7fcde4ddad3bff5f86c670b&pid=1-s2.0-S2667038024000097-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141056449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical evaluation of the Simplexa HSV 1 & 2 Direct assay for bronchoalveolar lavage specimens","authors":"Tung Phan ,&nbsp;David Gerlowski ,&nbsp;Melissa McCullough ,&nbsp;Jamie Gribschaw ,&nbsp;William Pasculle ,&nbsp;Alan Wells","doi":"10.1016/j.jcvp.2024.100177","DOIUrl":"https://doi.org/10.1016/j.jcvp.2024.100177","url":null,"abstract":"<div><p>Rapid laboratory testing is essential to detect HSV in the lower respiratory tract to allow rapid treatment decisions. We evaluated the clinical performance of the Simplexa HSV 1 &amp; 2 Direct assay in bronchoalveolar lavage. This assay is highly sensitive and specific in detecting HSV-1 and HSV-2 in bronchoalveolar lavage.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100177"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000024/pdfft?md5=ece77823fdc40a9bbaa724164eadacd6&pid=1-s2.0-S2667038024000024-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139713738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SARS-CoV-2 among liver transplant recipients: Clinical course and mutational analysis","authors":"Ruchita Chhabra ,&nbsp;Reshu Agarwal ,&nbsp;Pramod Gautam ,&nbsp;Varun Suroliya ,&nbsp;Shalini Thappar ,&nbsp;Shastry SM ,&nbsp;Arvind Tomar ,&nbsp;Chhagan Bihari ,&nbsp;Pratibha Kale ,&nbsp;Viniyendra Pamecha ,&nbsp;Ekta Gupta","doi":"10.1016/j.jcvp.2024.100181","DOIUrl":"https://doi.org/10.1016/j.jcvp.2024.100181","url":null,"abstract":"<div><h3>Background</h3><p>Very limited literature on the clinical course of COVID-19 among liver transplant recipients (LT) is available from India. The present study aimed to evaluate the clinical and mutational profile of SARS-CoV-2 among LT.</p></div><div><h3>Methodology</h3><p>This was a retrospective study including LT cases in whom SARS-CoV-2 RT-PCR testing was requested between April 2020 and December 2022. Detailed mutational analysis was performed by comparing LT COVID-19 positive study group i.e. LT-CoV(+) with two control groups. One including COVID-19 positive with underlying chronic liver disease (CLD) i.e. CLD-CoV(+) and other including COVID-19 positive outpatients without any underlying LD i.e. NLD-CoV(+)</p></div><div><h3>Results</h3><p>Among 213 cases, 48 (22.5 %) were positive [LT-CoV(+)] and the remaining 165 (77.5 %) were negative [LT-CoV(-)] for SARS-CoV-2. Of these, 49 % had mild, 14 % moderate and 37 % had severe COVID-19. Mortality was recorded in 11 (23 %) cases, the majority being non-vaccinated. Severe COVID-19 with intensive care requirement was significantly higher among recipients with &gt;5 years since transplant compared to recipients with <strong>≤</strong>5 years (<em>p</em> = 0.02). Among 40 samples subjected to whole genome sequencing, 19 (47.5 %) were Delta, 15 (37.5 %) Omicron, and 6 (15 %) were other variants. COVID-19 severity was significantly higher in LT-CoV(+/D) with no significant difference in mortality (<em>p</em> = 0.122). No significant differences in mutational load and in fraction of deleterious mutations were observed between LT-/CLD-/NLD-CoV(+) groups for either Delta or Omicron.</p></div><div><h3>Conclusion</h3><p>An overall fatality rate of 23 % was recorded among LT recipients. Longer duration since transplant was associated with severe clinical course. However, no significant difference in mutation load between studied groups was observed.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 2","pages":"Article 100181"},"PeriodicalIF":1.7,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000061/pdfft?md5=a4e9971e0b0b2f0abc2d9d0fb093443b&pid=1-s2.0-S2667038024000061-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141083785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the incidence of severe outcomes in outpatients with COVID-19 or seasonal influenza without risk factors: Retrospective analysis of a health insurance claims-database","authors":"H. Oshitani ,&nbsp;T. Komeda ,&nbsp;S. Fujita ,&nbsp;M. Asakawa ,&nbsp;Y. Kitanishi","doi":"10.1016/j.jcvp.2023.100175","DOIUrl":"10.1016/j.jcvp.2023.100175","url":null,"abstract":"<div><h3>Background</h3><p>To evaluate disease severity for coronavirus disease of 2019 (COVID-19), seasonal influenza (FLU) is often used as a control group for comparison. However, evidence regarding outpatients without risk factors for severe disease is insufficient to consider future treatment policies for these patients.</p></div><div><h3>Objectives</h3><p>To compare the risk of severe disease in patients without risk factors for severe disease who are diagnosed with COVID-19 or FLU.</p></div><div><h3>Study design</h3><p>This was a retrospective study analyzing a health insurance claims database (data collection: COVID-19, January 2020 through August 2022; FLU, October 2017 through September 2019). Outcome measures were incidences of severe events of hospitalization, respiratory and heart rate monitoring, oxygen therapy, ventilator use, and intensive care unit admission (within 28 days from diagnosis), and death (within the following month).</p></div><div><h3>Results</h3><p>Data from 575,293 patients were included in the COVID-19 group and from 1,095,698 patients in the FLU group, without risk factors. Adjusted odds ratios for all study outcomes were significantly higher for patients with COVID-19 than with FLU (&gt;3 times greater odds ratio for all severe events). For the population aged ≥18 years, there was also a significantly higher risk for all severe events with COVID-19 versus FLU. The incidence of severe events with COVID-19 among the population aged &lt;18 years was greatly reduced (versus ≥18 years), and risk for severe events was not significantly different with COVID-19 versus FLU.</p></div><div><h3>Conclusions</h3><p>These findings suggest that the medical need for specific treatment for patients with COVID-19 may be as high as for FLU.</p></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 1","pages":"Article 100175"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266703802300042X/pdfft?md5=6b1bb9f4a55ca251f552c5da9d552cee&pid=1-s2.0-S266703802300042X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The new normal post emergence of SARS-CoV-2","authors":"Catherine Moore","doi":"10.1016/j.jcvp.2024.100176","DOIUrl":"10.1016/j.jcvp.2024.100176","url":null,"abstract":"","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"4 1","pages":"Article 100176"},"PeriodicalIF":1.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2667038024000012/pdfft?md5=ca328966aea8d712fbdb41e2a67c38b0&pid=1-s2.0-S2667038024000012-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139538522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}